SCHEMBL31191259

SCHEMBL31191259

O=C(c1ccnc(COCC(F)(F)F)c1)C(F)F

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.41
▸ RAB9A P51151 1/20 0.38
▸ JMJD6 Q6NYC1 1/20 0.37
▸ EPHX2 P34913 1/20 0.35
▸ ACHE P22303 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ MAPT P10636 3/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ SCN9A Q15858 1/20 0.33
▸ GSK3B P49841 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ KCNT1 Q5JUK3 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5567317 0.85 ALDH1A1 (0.55) ALDH1A1RAB9AJMJD6NPSR1L3MBTL1
SCHEMBL31191302 0.81 KDM4E (0.47) ALDH1A1RAB9AJMJD6L3MBTL1MAPT
SCHEMBL31191107 0.79 EPHX2 (0.53) JMJD6EPHX2ACHENPSR1L3MBTL1
SCHEMBL31191251 0.77 MLYCD (0.41) ALDH1A1RAB9AJMJD6MAPTKMT2A
SCHEMBL31191159 0.76 LPL (0.34) ACHE
SCHEMBL31191208 0.74 CYP17A1 (0.38) ALDH1A1CYP2C19
SCHEMBL24208475 0.72 ALDH1A1 (0.41) ALDH1A1L3MBTL1MAPTKMT2AMEN1
SCHEMBL24208481 0.69 CFTR (0.40) ALDH1A1NPSR1L3MBTL1MAPTCYP3A4
SCHEMBL24208362 0.67 SLC6A4 (0.32) ALDH1A1
SCHEMBL13890805 0.67 EPHX2 (0.52) JMJD6EPHX2L3MBTL1MAPTGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4702025-A1 BICYCLIC HETEROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2026-03-04 — — EP disclosed
WO-2024223715-A1 BICYCLIC HETEROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2024-10-31 — — WO disclosed
Send feedback